Silexion Therapeutics Ltd. (SLXN)
Automate Your Wheel Strategy on SLXN
With Tiblio's Option Bot, you can configure your own wheel strategy including SLXN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SLXN
- Rev/Share 0.0
- Book/Share 0.3815
- PB 19.9234
- Debt/Equity 1.3465
- CurrentRatio 3.2242
- ROIC -2.1382
- MktCap 4404147.0
- FreeCF/Share -1.3451
- PFCF -0.483
- PE -3.0642
- Debt/Assets 0.4191
- DivYield 0
- ROE 2.7747
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player New Report Covers Silexion Therapeutics, A Unique Precision Oncology Player
Read More
Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year Silexion's new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional KRAS-driven tumor types with treatment markets estimated at over $30 Billion Dollars a year
Read More
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical Trials Collaboration Reinforces Silexion's Commitment to Bringing Transformative RNAi Cancer Therapies to Market as it Advances toward Clinical Trials
Read More
About Silexion Therapeutics Ltd. (SLXN)
- IPO Date 2024-08-16
- Website https://silexion.com
- Industry Biotechnology
- CEO Ilan Hadar
- Employees 11